Advertisement

Dan Ollendorf

Good, Bad, or Indifferent on Drug Pricing: A Value Benchmark Approach for Newly Launched Drugs in the United States.

April Rieger2023-12-14T13:11:11-05:00July 30th, 2015|Categories: Blog|Tags: benchmark reports, comparative effectiveness, Cost Effectiveness Analysis, Dan Ollendorf, Emerging Therapy Assessment and Pricing, evidence-based medicine, Health Economic Models, health outcomes models, ICER, Institute for Clinical and Economic Review, Patti Peeples, Pharmaceutical Industry, real world evidence, Steve Pearson, tHEORetically Speaking|

Swarali Tadwalker, MPH Hardly a day goes by without a new article being published in the mainstream press [...]